Publication:
2019 thai guidelines on the treatment of hypertension: Executive summary

Simple item page
dc.contributor.authorSirisawat Kunanonen_US
dc.contributor.authorPairoj Chattranukulchaien_US
dc.contributor.authorChavalit Chotruangnapaen_US
dc.contributor.authorWeerapat Kositanuriten_US
dc.contributor.authorKomsing Methavigulen_US
dc.contributor.authorThananya Boonyasirinanten_US
dc.contributor.authorPetch Rawdareeen_US
dc.contributor.authorSirakarn Tejavanijaen_US
dc.contributor.authorTuangsit Wataganaraen_US
dc.contributor.authorBancha Satirapojen_US
dc.contributor.authorWeranuj Roubsanthisuken_US
dc.contributor.authorNijasri C. Suwanwelaen_US
dc.contributor.authorSomkiat Sangwatanarojen_US
dc.contributor.authorRapeephon Kunjara Na Ayudhyaen_US
dc.contributor.authorSurapun Sitthisooken_US
dc.contributor.authorApichard Sukonthasarnen_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherVajira Hospitalen_US
dc.contributor.otherVichaiyut Hospitalen_US
dc.contributor.otherPhramongkutklao College of Medicineen_US
dc.contributor.otherFaculty of Medicine, Chulalongkorn Universityen_US
dc.contributor.otherCentral Chest Institute of Thailanden_US
dc.contributor.otherThai Hypertension Societyen_US
dc.date.accessioned2022-08-04T09:10:55Z
dc.date.available2022-08-04T09:10:55Z
dc.date.issued2021-10-01en_US
dc.description.abstractThe revision committee of the 2019 Thai Guidelines on the Treatment of Hypertension has reviewed new developments in the body of knowledge, together with the expertise in real-life clinical practice and evidence collected from clinical studies worldwide. The guidelines consist of newly highlighted key topics to ensure the guidelines remain up to date, user friendly, and suitable for the country's context. The guidelines still maintain the current office blood pressure (BP) cut-off point of 140/90 mmHg for the diagnosis of hypertension. The use of out-of-office BP measurements, including home BP monitoring (HBPM) or ambulatory BP monitoring (ABPM), is also advocated to confirm the diagnosis of hypertension. Target BP levels depend on the age of the patients, such as 120 to 130/70 to 79 mmHg for patients aged 18 to 65 years old, or 130 to 139/70 to 79 mmHg for patients over 65 years of age. There are five main groups of antihypertensive medication, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium-channel blockers, and thiazides or thiazide-like diuretics. Two types of medications should be started for most patients, except for frail elderly patients, patients with a relatively low initial BP of 140 to 149/90 to 99 mmHg, and low-risk patients, in which only one type of starting medication should be selected. Medication that involves a combination of two types in one pill should ideally be selected.en_US
dc.identifier.citationJournal of the Medical Association of Thailand. Vol.104, No.10 (2021)en_US
dc.identifier.doi10.35755/jmedassocthai.2021.10.12199en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-85117217350en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/77801
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85117217350&origin=inwarden_US
dc.subjectMedicineen_US
dc.title2019 thai guidelines on the treatment of hypertension: Executive summaryen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85117217350&origin=inwarden_US
Files
Collections
Scopus 2021